251 related articles for article (PubMed ID: 29036957)
21. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
23. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.
Shi X; Zhang J; Mo L; Shi J; Qin M; Huang X
Medicine (Baltimore); 2019 Apr; 98(15):e15180. PubMed ID: 30985706
[TBL] [Abstract][Full Text] [Related]
25. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates.
Viazis N; Argyriou K; Kotzampassi K; Christodoulou DK; Apostolopoulos P; Georgopoulos SD; Liatsos C; Giouleme O; Koustenis K; Veretanos C; Stogiannou D; Moutzoukis M; Poutakidis C; Mylonas II; Tseti I; Mantzaris GJ
Nutrients; 2022 Feb; 14(3):. PubMed ID: 35276991
[TBL] [Abstract][Full Text] [Related]
26. [Use of probiotics and probiotic-based immunomodulators as adjuvant therapy for Helicobacter pylori eradication].
Konorev MR; Andronova TM; Matveenko ME
Ter Arkh; 2016; 88(12):140-148. PubMed ID: 28635890
[TBL] [Abstract][Full Text] [Related]
27. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of compound
Ji W; Chen WQ; Tian X
BMJ Open; 2018 Oct; 8(10):e023131. PubMed ID: 30373781
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of
Yao G; Fan X; Lu D
J Int Med Res; 2023 Oct; 51(10):3000605231203841. PubMed ID: 37848344
[TBL] [Abstract][Full Text] [Related]
30. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Lee BH; Kim N; Hwang TJ; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
Helicobacter; 2010 Feb; 15(1):38-45. PubMed ID: 20302588
[TBL] [Abstract][Full Text] [Related]
31. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis.
Lu C; Sang J; He H; Wan X; Lin Y; Li L; Li Y; Yu C
Sci Rep; 2016 Mar; 6():23522. PubMed ID: 26997149
[TBL] [Abstract][Full Text] [Related]
32. [Drug susceptibility test guided therapy and novel empirical quadruple therapy for
Gou QY; Yu RB; Shi RH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 May; 38(5):670-673. PubMed ID: 28651409
[No Abstract] [Full Text] [Related]
33. Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis.
Nelwan EJ; Herdiman A; Kalaij AGI; Lauditta RK; Yusuf SM; Suarthana E
BMC Infect Dis; 2024 May; 24(1):505. PubMed ID: 38773400
[TBL] [Abstract][Full Text] [Related]
34. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China.
Wang L; Lin Z; Chen S; Li J; Chen C; Huang Z; Ye B; Ding J; Li W; Wu L; Jiang Y; Meng L; Du Q; Si J
Clin Microbiol Infect; 2017 Jun; 23(6):391-395. PubMed ID: 28077338
[TBL] [Abstract][Full Text] [Related]
35. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.
Cremonini F; Di Caro S; Covino M; Armuzzi A; Gabrielli M; Santarelli L; Nista EC; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2002 Nov; 97(11):2744-9. PubMed ID: 12425542
[TBL] [Abstract][Full Text] [Related]
36. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials.
Yu M; Zhang R; Ni P; Chen S; Duan G
PLoS One; 2019; 14(10):e0223309. PubMed ID: 31577828
[TBL] [Abstract][Full Text] [Related]
38. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Wang Z; Wu S
Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
[TBL] [Abstract][Full Text] [Related]
39. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
[TBL] [Abstract][Full Text] [Related]
40. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
